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ARTICLE
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in
adults with moderate-to-severe atopic dermatitis: combined results of four
randomized phase 3 trials
S. Barbarota , A. Wollenbergb , J. I. Silverbergc , M. Deleurand , G. Pellacanie , J. C. Armario-Hitaf ,
Z. Cheng, B. Shumelg, L. Eckerth, A. Gadkarig, Y. Lug and A. B. Rossii
aService de Dermatologie, Centre Hospitalier Universitaire de Nantes, Nantes, France; bDepartment of Dermatology and Allergy, Ludwig-
Maximilian University, Munich, Germany; cDepartment of Dermatology, The George Washington University School of Medicine and Health
Sciences, Washington, DC, USA; dDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark; eDepartment of Dermatology,
University of Modena and Reggio Emilia, Modena, Italy; fService of Dermatology, University Hospital of Puerto Real, University of Cadiz,
Cadiz, Spain; gRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; hSanofi, Chilly-Mazarin, France; iSanofi Genzyme, Cambridge, MA, USA
ABSTRACT
Background: Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the per-
sistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of mod-
erate-to-severe AD in Europe, USA, Japan and several other countries.
Objective: To assess dupilumab effects on SCORing Atopic Dermatitis (SCORAD) and component
scores (objective and subjective SCORAD) over time in adults with moderate-to-severe AD.
Methods: This post hoc analysis included 2,444 patients in four placebo-controlled, double-blind,
randomized, phase 3 trials. SOLO 1 and 2 (NCT02277743; NCT02277769) evaluated 16 weeks of dupilu-
mab monotherapy against placebo. CAFE (NCT02755649) and CHRONOS (NCT02260986) evaluated dupi-
lumab with concomitant topical corticosteroids (TCS) against TCS alone for 16 and 52weeks,
respectively.
Results: 2,444 patients randomized to treatment in SOLO 1 and 2 (N¼ 1,379), CAFE (N¼ 325) and
CHRONOS (N¼ 740) were analyzed. Dupilumab treatment significantly improved overall SCORAD and
individual components as early as Week 1 or 2, with significant and clinically meaningful differences
vs. control through end of treatment (p< .0001). These results occurred irrespective of dupilumab
regimen, 300mg subcutaneously weekly or every 2weeks.
Conclusions: In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment
with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD out-
comes vs. placebo or TCS alone.
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Atopic dermatitis (AD) is a complex, chronic relapsing skin dis-
ease characterized by underlying type 2 inflammation, with
recent evidence suggesting it is a systemic disease (1–5).
Diagnosis is based on clinician assessment of signs, including
erythema, edema, oozing, lichenification and xerosis that can be
localized or affect a widespread body surface area. Moderate-to-
severe AD is highly symptomatic and can have a profound
multidimensional burden on patients (6–8). Frequent, intense
pruritus and sleep loss are the most recognized and impactful
symptoms contributing to reduced quality of life (QoL) and
worse psychological and overall health status among
patients (1,9–16).
Numerous clinical tools have been developed to assess AD
severity. These tools are used primarily in clinical trials but can
also be used for clinical monitoring and to guide treatment
decisions (17). The most commonly used and validated scoring
systems are the Eczema Area and Severity Index (EASI), SCORing
Atopic Dermatitis (SCORAD) and Patient-Oriented Eczema
Measure (POEM) (18–21).
Developed and validated in the 1990s by the European Task
Force on AD (ETFAD), SCORAD is recommended by European AD
guidelines and evaluates investigator-reported affected body sur-
face area and severity of signs (objective component) as well as
patient-reported symptoms of pruritus and sleep loss (subjective
component) (22–24). Established severity strata reflect mild, mod-
erate and severe disease, with thresholds differing depending on
the specific population (25,26). The current ETFAD guidelines on
diagnosis and treatment of AD and the ETFAD position paper on
AD recommend using SCORAD for overall disease severity and
have anchored therapy step-up/step-down to SCORAD levels of
25 and 50, respectively (5,24,27). The ETFAD has also proposed a
grading scale to assess disease severity based on the objective
component of SCORAD only (o-SCORAD), namely the extent of
disease and intensity of signs (23).
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EASI and o-SCORAD/SCORAD have several key differences
(Table S1). EASI gives a higher weighting to the area of involve-
ment (60% of the score) and o-SCORAD and SCORAD to inten-
sity of signs (75% and 60%, respectively), making
o-SCORAD/SCORAD more suitable for measuring localized, severe
AD than EASI (28). EASI evaluates area and severity in four differ-
ent body regions, whereas SCORAD uses overall body surface cal-
culation using the rule of nines, with severity graded in a target
lesion. Finally, EASI assesses four signs (erythema/edema/lichenifi-
cation/excoriation), whereas SCORAD also assesses oozing/crust-
ing and xerosis in nonlesional skin, and subjective patient
assessment of pruritus and sleep loss. Thus, EASI and SCORAD
provide different assessments of disease severity.
Treatment options are limited for adults with moderate-to-
severe AD uncontrolled with currently approved topical and/or
systemic treatments. Long-term use of systemic immunosup-
pressants is not recommended due to unfavorable benefit-risk
profiles. Dupilumab, a fully human VelocImmuneVR -derived
(29,30) monoclonal antibody, blocks the shared receptor subunit
for interleukin (IL)-4 and IL-13, thus inhibiting signaling of both
IL-4 and IL-13. Dupilumab is approved for patients with type 2
inflammatory diseases, including AD, asthma, and chronic rhino-
sinusitis with nasal polyps (31,32).
Four randomized, double-blind, placebo-controlled, phase 3
trials involving 2,444 adult patients with moderate-to-severe AD
have demonstrated efficacy and safety of dupilumab with or
without concomitant topical corticosteroids (TCS) (33–35). The
objective of this manuscript is to report the effects of dupilumab
on SCORAD outcomes in adults with moderate-to-severe AD
included in these dupilumab phase 3 studies, either when used
as a monotherapy or in combination with concomitant TCS.
Methods
Study design
This post hoc analysis includes data from four randomized, double-
blind, placebo-controlled, parallel-group, phase 3 clinical trials that
evaluated dupilumab treatment in 2,444 adults with moderate-to-
severe AD. Patients in these trials received dupilumab monother-
apy (300mg weekly [qw] or every 2weeks [q2w]; LIBERTY AD
SOLO 1 [NCT02277743] and LIBERTY AD SOLO 2 [NCT02277769],
data pooled in this analysis) (33) or dupilumab with concomitant
TCS (300mg qw or q2w; LIBERTY AD CAFE [NCT02755649](34) and
LIBERTY AD CHRONOS [NCT02260986]) (35).
Key study details for SOLO 1 and 2, CAFE and CHRONOS are
provided in Table S2. Detailed methodology and primary effi-
cacy and safety results have been reported previously (33–35).
Of note, the CAFE study included a population with more severe
disease unresponsive, intolerant or contraindicated to ciclo-
sporin A.
These trials were approved by their respective institutional
review boards and conducted in accordance with the ethical
principles outlined in the Declaration of Helsinki, the
International Conference on Harmonisation Good Clinical
Practice guideline and applicable regulatory requirements.
Outcomes assessed
SCORAD includes three components (22) (Table S3): Part A, the
extent of disease (investigator-assessed); Part B, the intensity of
signs of disease (investigator-assessed); and Part C, symptoms
(patient-assessed). Total SCORAD is calculated as: A/5þ 7B/2þC,
with a maximum possible score of 103; higher scores indicate
worse disease. The extent of disease (Part A), the intensity of signs
(Part B) and symptoms (Part C) account for 19.4, 61.1, and 19.4%
of the total score, respectively. o-SCORAD includes the objective
components of SCORAD (Parts A and B mentioned previously)
(23), with area and signs accounting for 24% and 76% of the total
score, respectively. o-SCORAD is calculated as: A/5þ 7B/2, for a
maximum possible score of 83; higher scores indicate worse dis-
ease. The within-patient clinically meaningful changes have been
estimated as 8.7 and 8.2 for SCORAD and o-SCORAD, respectively
(36). Subjective assessment of pruritus and sleep loss is recorded
by the patient or relative on a visual analog scale (VAS) based on
an average value over the past 3days or nights: 0: no pruritus or
sleep loss;10: worst imaginable pruritus or sleep loss.
SCORAD was assessed at screening, baseline, Weeks 1, 2, 4,
6, 8, 12, and 16 in all studies, and every 4 weeks thereafter
through Week 52 in CHRONOS. The following severity bands
were used in these analyses: for SCORAD (26), clear (0–9.9), mild
(10.0–28.9), moderate (29.0–48.9) and severe (49.0–103); for
o-SCORAD (26) clear (0–7.9), mild (8.0–23.9), moderate
(24.0–37.9) and severe (38.0–83); for SCORAD pruritus VAS (37)
and sleep loss VAS: none (0), mild (>0 to <4), moderate (4 to
<7), severe (7 to 9) and very severe pruritus (9).
This analysis includes results over time for each study as
SCORAD, o-SCORAD, SCORAD-50 (50% improvement from base-
line in total SCORAD), percentage of patients achieving the clinic-
ally meaningful change for SCORAD and o-SCORAD, SCORAD
component scores (Parts A, B, and C), percent change from base-
line in total SCORAD, categorical changes in SCORAD severity
according to the severity strata outlined previously (26) categor-
ical changes in individual signs severity over time, the percent
reduction in Parts A, B, and C, change in absolute values from
baseline to Week 16 or 52 for SCORAD, o-SCORAD, Part A, Part B
(erythema, edema/papulation, excoriation, lichenification, oozing/
crusting and dryness on nonlesional areas) and individual symp-
toms (pruritus VAS and sleep loss VAS).
Statistical analysis
Efficacy analyses were performed on the full analysis set, which
included all randomized patients. For continuous outcomes,
patients missing an assessment or who received rescue treat-
ment were considered ‘nonresponders’ (censoring) and imputed
using the multiple imputation method; p values were assessed
using an analysis of covariance model with baseline measure-
ment as a covariate and the treatment, region, baseline
Investigator’s Global Assessment (IGA) strata, and study identi-
fier (for SOLO studies only) as fixed factors. The p values for cat-
egorical endpoints were derived by a Cochran-Mantel-Haenszel
(CMH) test stratified by region and baseline IGA strata, with a
study identifier added as an additional factor for the SOLO
pooled analysis. For categorical outcomes, patients who
received rescue treatment were considered nonresponders after
rescue treatment use (nonresponder imputation). Significance
values were considered nominal for all analyses. For Sankey
plots of changes in SCORAD severity over time, values were set
to missing after rescue treatment, and missing total SCORAD
scores were set to the highest category (severe).
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Results
Patients
All 2,444 patients randomized to treatment in SOLO 1 and 2
(N¼ 1,379), CAFE (N¼ 325) and CHRONOS (N¼ 740) were
included in this analysis (Table 1). Detailed baseline demograph-
ics and characteristics for each study have been published previ-
ously (33–35) and were similar across studies. Median age was
34.0–40.5 years for each treatment group across studies, and the
median disease duration was 25.0–32.0 years (Table 1).
Baseline SCORAD details are provided in Table 1. Median scores
in each treatment group were similar across studies and ranged
between 64.1–69.7 for total SCORAD, 52.4–57.2 for o-SCORAD,
51.0–58.8 for Part A, 12.0–13.0 for Part B and 10.4–13.7 for Part C.
Efficacy analysis by SCORAD and SCORAD components
As both dupilumab doses had similar results, only those from
the approved 300mg q2w treatment and control (placebo or
placeboþ TCS) groups are reported in the text for simplicity.
Least squares (LS) mean total SCORAD and o-SCORAD scores
declined in all treatment groups over time, with mean values
significantly lower with dupilumab vs. control in each study, as
early as the first timepoint measured (Week 1, Figure 1). The
proportion of patients achieving SCORAD-50 was greater with
dupilumab vs. control in each study (Figure 1), with a signifi-
cantly higher proportion observed with dupilumab as early as
Week 1 (monotherapy), Week 2 (CHRONOS) and Week 4 (CAFE).
Of all patients treated with dupilumab q2w across all studies,
95.7% achieved a clinically meaningful change for SCORAD
(8.7-point improvement) and 79.9% for o-SCORAD (8.2-point
improvement) (36), (p< .0001 vs. control for both).
When looking at individual components, dupilumab treat-
ment resulted in statistically significant improvements as meas-
ured by the extent of disease (SCORAD Part A), the intensity of
signs (Part B and individual signs) and intensity of symptoms
(Part C and individual symptoms of pruritus and sleep loss) vs.
the control in each study (Figure 2). These significant differences
were observed as early as the first timepoint measured (Week 1)
for most components and continued to improve or were main-
tained until the end of treatment (16 or 52weeks).
With respect to symptoms, 54.5, 75.7, and 72.7% of patients
had mild or no pruritus and 66.3, 85.0, and 73.5% had mild or
no sleep loss at end of treatment in SOLO, CAFE and CHRONOS,
respectively (Figure 3).
The percent change in total SCORAD from baseline was
greater with dupilumab vs. control at the end of treatment in
all studies (p< .0001 for both dupilumab regimens vs. control).
At the end of the treatment period, the LS mean percent
changes in SCORAD were 54.3, 58.3, and 69.4% with dupi-
lumab vs. 24.0, 29.5, and 47.3% with control in SOLO
pooled, CAFE and CHRONOS, respectively.
The percentage of patients in each SCORAD severity category
shifted over time, with greater movement from ‘severe’ or
‘moderate’ disease at baseline to ‘mild’ disease or ‘clear’ at the
end of treatment with dupilumab vs. control (Figure 4).
The majority of patients in the control arms had scores corre-
sponding to ‘severe’ disease by the end of treatment. In con-
trast, the majority of dupilumab-treated patients had scores
corresponding to ‘clear’ or ‘mild’ disease in CAFE and CHRONOS
Dupilumab 300 mg qw + TCS (n = 319)
Dupilumab 300 mg q2w + TCS (n = 106)
Control group (n = 315)
(c) CHRONOS, 52 weeks with concomitant TCS
Dupilumab 300 mg qw + TCS (n = 110)
Dupilumab 300 mg q2w + TCS (n = 107)
Control group (n = 108)
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Figure 1. LS mean total SCORAD score (score range 0–103), o-SCORAD (score range 0–83) and SCORAD-50 over time: (a) SOLO 1 and 2 (pooled data), 16-week
monotherapy; (b) CAFE, 16weeks with concomitant TCS; (c) CHRONOS, 52weeks with concomitant TCS. p < .05 vs. placebo/control; p < .01 vs. placebo/con-
trol; p < .0001 vs. placebo/control. LS: least squares; o-SCORAD: objective SCORing Atopic Dermatitis; qw: weekly; q2w: every 2 weeks; SCORAD: SCORing
Atopic Dermatitis; SCORAD-50: 50% reduction from baseline in SCORing Atopic Dermatitis; SE: standard error; TCS: topical corticosteroids.
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and ‘clear,’ ‘mild’ or ‘moderate’ disease in SOLO by the end
of treatment.
Categorical changes in signs severity score at each timepoint
through Week 16 in patients treated with dupilumab monother-
apy or placebo in SOLO 1 and 2 are presented in Figure 5 and
in Figure S1 for CAFE and CHRONOS. LS mean percent change
in sign intensity score over time is shown in Figure S2. The dis-
tribution across severity groups in all individual signs shifted
over time. Dupilumab showed significant improvement in most
signs vs. placebo as early as Week 1 with a greater proportion
of patients with absent or mild signs by the end of treatment,
whereas a greater proportion of patients had severe signs in
the placebo group. Table S4 shows by which week the improve-
ment in signs was significant vs. control. By Week 16, the major-
ity of patients had mild or absent signs (except for erythema
with monotherapy) in dupilumab vs. the majority of patients
having moderate or severe signs in the control arm (Figure 5,
Figure S1).
At the end of treatment (Week 16 in SOLO and CAFE and
Week 52 in CHRONOS), dupilumab-treated patients showed con-
sistent improvements assessed as LS mean percent reduction in
SCORAD Part A (area), Part B (signs) and Part C (symptoms)
(Figure 6). Changes in absolute values from baseline (diamond)
to Week 16/52 (dot) for SCORAD components are shown in the
rainbow plots in Figure 7 for the control and q2w regimens
across all studies. In all three studies, dupilumab vs. control led
to greater improvements in total SCORAD, o-SCORAD, the
extent of disease and individual signs and symptoms (VAS prur-
itus and VAS sleep loss), with 1 grade of improvement in
severity for those outcomes based on established severity strata.
Figure 8 shows examples of patients treated with dupilumab
monotherapy and their improvement in all SCORAD assessments
from baseline to Week 16.
Safety
Detailed safety results have been previously reported (33–35).
Overall, dupilumab had a favorable safety profile across all stud-
ies. Treatment-emergent adverse events occurred at similar rates
across treatment groups. Conjunctivitis and injection-site reac-
tion, mostly of mild-to-moderate severity, were more frequent
in the dupilumab-treated groups in all studies, whereas AD
exacerbations and skin infections occurred more frequently in
patients in the control groups. Conjunctivitis and infections in
dupilumab clinical studies have been described elsewhere
(38,39). Because no clinically significant laboratory abnormalities
have been identified in the dupilumab clinical program, no







































































































































































































































































































































































































(c) CHRONOS, 52 weeks with concomitant TCS
Dupilumab 300 mg qw + TCS (n = 319)
Dupilumab 300 mg q2w + TCS (n = 106)
Control group (n = 315)
(b) CAFÉ, 16 weeks with concomitant TCS
Dupilumab 300 mg qw + TCS (n = 110)
Dupilumab 300 mg q2w + TCS (n = 107)
Control group (n = 108)
(a) Pooled SOLO 1 and 2, 16 weeks monotherapy
Dupilumab 300 mg qw (n = 462)
Dupilumab 300 mg q2w (n = 457)
Placebo (n = 460)
Figure 2. LS mean SCORAD scores for Part A (extent of disease [BSA] score, 0–100), Part B (signs intensity score, 0–18), pruritus VAS score (0–10), and sleep loss
VAS score (0–10) over time: (a) SOLO 1 and 2 (pooled data), 16-week monotherapy; (b) CAFE, 16weeks with concomitant TCS; (c) CHRONOS, 52weeks with con-
comitant TCS. p < .05 vs. placebo; †p < .01 vs. placebo; p < .001; p < .0001 vs. placebo. BSA: body surface area; LS: least squares; qw: weekly;
q2w: every 2 weeks; SCORAD: SCORing Atopic Dermatitis; SE: standard error; TCS: topical corticosteroids; VAS: visual analog scale.
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(b) CAFÉ, 16 weeks with concomitant TCS (c) CHRONOS, 52 weeks with concomitant TCS
Clear (0–9.9) Mild (10.0–28.9) Moderate (29.0–48.9) Severe (49.0–103)

















































































































































































































































































































































































































Figure 4. Percentage of patients in each total SCORAD score severity category over time, by study: (a) SOLO 1 and 2 (pooled data), 16-week monotherapy;
(b) CAFE, 16weeks with concomitant TCS; (c) CHRONOS, 52weeks with concomitant TCS. Values were set to missing after rescue treatment; missing total SCORAD
scores were set to the highest category (severe). q2w: every 2 weeks; SCORAD: SCORing Atopic Dermatitis; TCS: topical corticosteroids.






(a) Pooled SOLO 1 and 2,
16 weeks monotherapy
(b) CAFÉ, 16 weeks
with concomitant TCS
(c) CHRONOS, 52 weeks
with concomitant TCS
(d) Pooled SOLO 1 and 2,
16 weeks monotherapy
(e) CAFÉ, 16 weeks
with concomitant TCS












































































































































































































































































































































































































































































































































































































































































































































































































Figure 3. Percentage of patients in each severity category for pruritus over time, by study: (a) SOLO 1 and 2 (pooled data), 16-week monotherapy; (b) CAFE,
16weeks with concomitant TCS; (c) CHRONOS, 52 weeks with concomitant TCS; and percentage of patients in each severity category for sleep loss VAS over time,
by study: (d) SOLO 1 and 2 (pooled data), 16-week monotherapy; (e) CAFE, 16 weeks with concomitant TCS; (f) CHRONOS, 52 weeks with concomitant TCS.
Values were set to missing after rescue treatment; missing total SCORAD scores were set to the highest category (severe). q2w: every 2 weeks; TCS: topical corti-
costeroids; VAS: visual analog scale.
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Discussion
These analyses demonstrate that dupilumab 300mg q2w, as
monotherapy and in combination with TCS, significantly
improves SCORAD outcomes in adults with moderate-to-severe
AD compared with placebo with or without TCS. These improve-
ments were observed throughout treatment in four randomized
controlled trials, which included 2,444 patients in total.
Furthermore, statistically significant improvements with dupilu-
mab were observed in all components of the SCORAD score,
including o-SCORAD (extent of disease [Part A] and intensity of
signs [Part B]) and subjective SCORAD (symptoms: pruritus and
sleep loss [Part C]).
In dupilumab-treated adults, rapid improvements in the
extent of affected area, signs and symptoms were observed
in the first weeks of treatment, and improvements were sus-
tained over the 16- and 52-week treatment periods. Most out-
comes (SCORAD, o-SCORAD, the extent of disease, pruritus,
sleep loss and the majority of individual signs) significantly
improved after a single dose of dupilumab; these improve-
ments were progressive over 16–28weeks and sustained
over 52weeks.
Absent Mild Moderate Severe
Sign Placebo Dupilumab 300 mg q2w
Examples of photos of patients
treated with dupilumab at







































































































































































































































































































































































































































































































































































































































































































Figure 5. Distribution of signs severity over time in patients treated with placebo and dupilumab 300mg q2w: SOLO 1 and 2, 16-week monotherapy. Missing
SCORAD scores set to the highest value (severe). Severity strata for severity grading are absent (0), mild (1), moderate (2), and severe (3). q2w: every 2 weeks;
SCORAD: SCORing Atopic Dermatitis.
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(a) Pooled SOLO 1 
     and 2,16 weeks 
     monotherapy
(b) CAFÉ, 16 weeks 
     with concomitant 
     TCS
(c) CHRONOS, 52 
     weeks with 
     concomitant TCS
Placebo/control Dupilumab 300 mg q2w



























































































Figure 7. Change in LS mean absolute values from baseline (diamond) to Week 16/52 (dot) for SCORAD components: (a) SOLO 1 and 2 (pooled data), 16-week
monotherapy; (b) CAFE, 16 weeks with concomitant TCS; (c) CHRONOS, 52 weeks with concomitant TCS. BSA: body surface area; LS: least squares; q2w: every 2
weeks; SCORAD: SCORing Atopic Dermatitis; o-SCORAD: objective SCORAD; TCS: topical corticosteroids; VAS: visual analog scale.
Part A














Dupilumab 300 mg q2w
Control
Dupilumab 300 mg q2w + TCS
Control
Dupilumab 300 mg q2w + TCS
Part A























Figure 6. LS mean percent reduction in Part A (area), Part B (signs) and Part C (symptoms): (a) SOLO 1 and 2 (pooled data), 16-week monotherapy; (b) CAFE,
16-week with concomitant TCS; (c) CHRONOS, 52-week with concomitant TCS. Lines closer to the outer edge of the spider plot represent greater improvement
from baseline. LS: least squares; qw: weekly; q2w: every 2 weeks; SCORAD: SCORing Atopic Dermatitis; TCS: topical corticosteroids.











































































Figure 8. Examples of patients treated with dupilumab monotherapy and their individual improvement in SCORAD outcomes. Photos correspond to the target
lesion assessed for SCORAD in SOLO studies (dupilumab monotherapy) in q2w group (approved dose). (a) 64-year-old patient, AD for 19 years; (b) 25-year-old
patient, AD for 18 years. The spider graphics show LS mean percent reduction in each outcome; lines closer to the outer edge of the spider plot represent greater
improvement from baseline. The rainbow graphics display change in LS mean absolute values from baseline (diamond) to Week 16 (dot) for each outcome. BSA:
body surface area; LS; least squares; q2w: every 2 weeks; SCORAD: SCORing Atopic Dermatitis; o-SCORAD: objective SCORAD; VAS: visual analog scale.
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The use of scores to document disease severity and assess
the effect of treatment is increasing with the availability of new
treatments for AD. Although EASI score is recommended by the
Harmonizing Outcome Measures for Eczema (HOME) initiative as
the core outcome instrument for measuring AD signs in clinical
trials (21), both EASI and o-SCORAD were identified as exten-
sively validated among 16 instruments, and SCORAD is used in
both clinical trials and clinical practice by dermatologists glo-
bally. Furthermore, o-SCORAD was endorsed by HOME as a sec-
ondary scoring tool to evaluate objective AD signs in clinical
trials in addition to EASI, whenever possible. Although both
EASI and o-SCORAD evaluate affected area and intensity of
signs, EASI places a higher weighting on the area and
o-SCORAD places a higher weighting on signs. Vakharia et al
(41) found that SCORAD had a numerically stronger correlation
with patient-reported severity than all other measures exam-
ined, including EASI. SCORAD is also more sensitive in the evalu-
ation of localized severe lesions and lesions in sensitive areas
whose function may be compromised, assigning additional
points for lesions located on hands, feet, and genitals (23).
Moreover, both SCORAD and its patient-oriented variant (PO-
SCORAD) are available as free apps in multiple languages, ena-
bling patients to perform a self-assessment of AD severity. The
correlation of SCORAD and PO-SCORAD has been demonstrated
(42), and recently the strata for PO-SCORAD was defined in
adults with AD: mild (1–27), moderate (28–56), and severe
(57–103) (43).
Overall, these data show that most adults respond to dupilu-
mab, as shown by improvements in signs, symptoms and dis-
ease severity measured by SCORAD. Furthermore, the data add
to prior evidence demonstrating the benefit of dupilumab with
regard to improvements in signs and symptoms of AD, as well
as QoL and psychological health, as reported with other key
treatment outcome measurements, including EASI, the Peak
Pruritus Numerical Rating Scale (NRS), POEM, the Dermatology
Life Quality Index and the Hospital Anxiety and Depression
Scale (33–35,44).
Of note, observed improvements in pruritus VAS in response
to dupilumab differ from those measured by the Peak Pruritus
NRS (45), despite both being 10-point scales of pruritus severity.
These differences may be because they assess pruritus differ-
ently. In the SCORAD VAS, patients are asked: ‘What was the
average itch in the last 3 days?’ whereas the Peak Pruritus NRS
asked, ‘On a scale of 0–10, what was the worst level of itch dur-
ing the last 24 hours?’ (46). Interpreting results from various
studies must consider these different questions. Our analyses
show that the vast majority of patients achieved a clinically sig-
nificant benefit in pruritus and sleep loss with a score corre-
sponding to mild or absent by the treatment end, a
considerable positive impact given that the majority of patients
had severe pruritus at baseline.
A clear improvement in lichenification was observed even in
the 16-week studies, with most patients moving from moder-
ate/severe to none/mild (Figure 5). Lichenification is considered
the AD sign most resistant to treatment, with improvement
likely taking longer than with other signs. Lichenification in AD
involves epidermal acanthosis and dermal fibrosis (47). A pos-
sible explanation for early improvement with dupilumab may be
that IL-4 and IL-13 are not only associated with a defective bar-
rier with increased permeability to allergens but also increase
collagen synthesis through ERK pathway activation (48). By
blocking the IL-4 receptor, dupilumab may induce tissue remod-
eling in both the epidermis and dermis.
Strengths of this analysis include an examination of four
large, multinational randomized controlled trials, assessment of
dupilumab as monotherapy and in combination with TCS, and
multiple sensitivity analyses. Additionally, all efficacy measures
have strengths and limitations, and SCORAD adds another
means to confirm dupilumab efficacy across both physician- and
patient-assessed signs and symptoms. Limitations include the
post hoc nature of some analyses.
In conclusion, in all our large phase 3 trials, dupilumab
administered as monotherapy or with concomitant TCS resulted
in rapid, sustained and statistically and clinically significant
improvements in total SCORAD and all component scores for
the extent of disease and intensity of signs and symptoms com-
pared with control groups of adults with uncontrolled AD.
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